 |
|
|
| |
A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV
IL28B-CC Genotype-1-Infected Subjects
|
| |
| |
Eric Lawitz1, Fred Poordad2, Kris V. Kowdley3, Donald Jensen4, Daniel E. Cohen5, Sara Siggelkow5, Karen Wikstrom5, Lois Larsen5, Rajeev M. Menon5, Thomas Podsadecki5, Barry Bernstein5
1: Alamo Medical Research, San Antonio, TX, 2: Cedars-Sinai Medical Center, Los Angeles, CA, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, IL 5: Abbott, Abbott Park, IL
|
| |
|
|
|
|
|
